Among patients with end-stage kidney disease (ESKD) on dialysis, hyperkalemia is a common, potentially life-threatening ... The gold standard therapy for patients with heart failure with reduced ejection fraction (HFrEF) and chronic kidney ... Treatment for heart failure with reduced ejection fraction HFrEF) and chronic kidney disease includes use of ... The potassium binder patiromer has a favorable safety profile when compared with sodium polystyrene (SPS). Yoshitsugu ... Patients with chronic kidney disease (CKD) who experience hyperkalemia are at increased risk for morbidity and ... Hospitalized patients often develop hyperkalemia, a common electrolyte disorder. However, according to Katherine E. Di ... Patiromer (Veltassa®; Vifor Phrma, Inc.), a sodium-free potassium binder, is used for the management of hyperkalemia in ... Hyperkalemia (serum potassium level >5.0 mEq/L) is associated with cardiac dysrhythmias, sudden cardiac death, and ... In the United States, the overall prevalence of end-stage kidney disease (ESKD) is increasing; in 2016 there were ... Spironolactone is known to be effective in reducing blood pressure in patients with resistant hypertension; however, the ... Patiromer, a sodium-free potassium binder approved for treating hyperkalemia in adults is not currently approved for use ... Patiromer, a sodium-free, nonabsorbed potassium binder is approved for the treatment of hyperkalemia. Results from the ... Washington, DC—Researchers, led by Matthew Weir, MD, conducted a post hoc analysis to examine the efficacy and ... Washington, DC—Patiromer, a sodium-free, nonabsorbed potassium binder is approved for the treatment of hyperkalemia. ... An oral potassium binding polymer (patiromer) aided in the use of spironolactone in a subset of patients with heart ... Csaba P. Kovesdy, MD, and colleagues recently conducted a retrospective cohort study to examine the incidence of ... The novel sodium-free, non-absorbed potassium binder patiromer is approved for the treatment of hyperkalemia. Elvira O. ...